The Impact of Methylphenidate on Pubertal Maturation and Bone Age in ADHD Children and Adolescents: Results from the ADHD Drugs Use Chronic Effects (ADDUCE) Project

Carucci S.

Primo

Writing – Original Draft Preparation

;Zuddas A.

Secondo

Writing – Review & Editing

;Lampis A.

Writing – Review & Editing

;Man K. K. C.;Balia C.

Writing – Review & Editing

;Buitelaar J.;Danckaerts M.;Dittmann R. W.;Donno F.

Writing – Review & Editing

;Falissard B.;Gagliano A.

Writing – Review & Editing

;Garas P.;Hage A.;Hollis C.;Inglis S. K.;Konrad K.;Kovshoff H.;Liddle E.;McCarthy S.;Neubert A.;Nagy P.;Rosenthal E.;Sonuga-Barke E. J. S.;Wong I. C. K.;Banaschewski T.;Coghill D.

2024-01-01

---

Abstract

Objective: The short-term safety of methylphenidate (MPH) has been widely demonstrated; however the long-term safety is less clear. The aim of this study was to investigate the safety of MPH in relation to pubertal maturation and to explore the monitoring of bone age. Method: Participants from ADDUCE, a two-year observational longitudinal study with three parallel cohorts (MPH group, no-MPH group, and a non-ADHD control group), were compared with respect to Tanner staging. An Italian subsample of medicated-ADHD was further assessed by the monitoring of bone age. Results: The medicated and unmedicated ADHD groups did not differ in Tanner stages indicating no higher risk of sexual maturational delay in the MPH-treated patients. The medicated subsample monitored for bone age showed a slight acceleration of the bone maturation after 24 months, however their predicted adult height remained stable. Conclusion: Our results do not suggest safety concerns on long-term treatment with MPH in relation to pubertal maturation and growth.